Greenwich LifeSciences (NASDAQ: GLSI) Expands FLAMINGO-01 Trial with City of Hope Site
Key Developments Greenwich LifeSciences (NASDAQ: GLSI), a clinical-stage biopharmaceutical company, announced the addition of the City of Hope as a new clinical site for its ongoing FLAMINGO-01 Phase III trial. This trial evaluates GLSI-100, an immunotherapy designed to prevent breast cancer recurrences and designated as a Fast Track therapy. The Company is expanding its clinical reach across the United States by incorporating new sites, enhancing patient access to this promising…









